Aleksandra Mieczkowska
Overview
Explore the profile of Aleksandra Mieczkowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grzadka E, Starek-Wojcicka A, Krajewska M, Matusiak J, Orzel J, Studzinski M, et al.
Sci Rep
. 2025 Jan;
15(1):455.
PMID: 39747393
The main aim of this work was to study the chemical composition of eighteen ground coffees from different countries and continents with regard to the content of hazardous substances as...
2.
Lesage C, Guihard P, De Fourmestraux C, Gauthier O, Weiss P, Guicheux J, et al.
J Vis Exp
. 2024 Oct;
(211).
PMID: 39400183
The extensive characterization of tissue mineralization in the context of bone regeneration represents a significant challenge, given the numerous modalities that are currently available for analysis. Here, we propose a...
3.
Mieczkowska A, Mabilleau G
Calcif Tissue Int
. 2023 Jun;
113(3):344-353.
PMID: 37278762
Enzymatic cross-linking of the bone collagen is important to resist to crack growth and to increased flexural strength. In the present study, we proposed a new method for assessment of...
4.
Mieczkowska A, Bouvard B, Legrand E, Mabilleau G
Front Endocrinol (Lausanne)
. 2021 Aug;
12:721506.
PMID: 34421828
Bone tissue is organized at the molecular level to resist fracture with the minimum of bone material. This implies that several modifications of the extracellular matrix, including enzymatic collagen crosslinking,...
5.
Mieczkowska A, Millar P, Chappard D, Gault V, Mabilleau G
Calcif Tissue Int
. 2020 Jul;
107(3):281-293.
PMID: 32642787
The aim of this study is to compare head-to-head the effects of dapagliflozin and liraglutide on bone strength and bone material properties in a pre-clinical model of diabetes-obesity. Combined low-dose...
6.
Vyavahare S, Mieczkowska A, Flatt P, Chappard D, Irwin N, Mabilleau G
Peptides
. 2019 Nov;
125:170207.
PMID: 31765668
Receptors to glucose-dependent insulinotropic polypeptide (GIP), have been identified on bone and GIP receptor (GIPr) knockout mice exhibit reduced bone strength and quality. Despite this, little is known on the...
7.
Mansur S, Mieczkowska A, Flatt P, Chappard D, Irwin N, Mabilleau G
Front Endocrinol (Lausanne)
. 2019 Feb;
10:51.
PMID: 30809192
Type 2 diabetes mellitus (T2DM) has recently been recognized as a significant risk factor for bone fragility. Careful investigations of bone mechanical properties in human studies suggested possible alterations of...
8.
Mansur S, Mieczkowska A, Flatt P, Chappard D, Irwin N, Mabilleau G
Calcif Tissue Int
. 2018 Dec;
104(4):437-448.
PMID: 30564859
Type 2 diabetes mellitus is recognized as a significant risk factor for fragility of bone. Among the newer anti-diabetic agents, dipeptidyl peptidase-4 inhibitors (DPP4i) have been reported to decrease the...
9.
Mabilleau G, Gobron B, Mieczkowska A, Perrot R, Chappard D
J Endocrinol
. 2018 Aug;
239(2):215-227.
PMID: 30121578
Glucose-dependent insulinotropic polypeptide (GIP) has been recognized in the last decade as an important contributor of bone remodelling and is necessary for optimal bone quality. However, GIP receptors are expressed...
10.
Mabilleau G, Perrot R, Mieczkowska A, Boni S, Flatt P, Irwin N, et al.
Bone
. 2016 Jul;
91:102-12.
PMID: 27451082
A role for glucose-dependent insulinotropic polypeptide (GIP) in controlling bone resorption has been suspected. However uncertainty remains to identify whether GIP act directly on osteoclasts. The aim of the present...